Ferring 
Welcome,         Profile    Billing    Logout  
 29 Products   56 Diseases   29 Products   154 Trials   7457 News 


12345678910111213...9798»
  • ||||||||||  Review, Journal:  Hidradenitis Suppurativa Treatment During Pregnancy and Lactation: Navigating Challenges. (Pubmed Central) -  Jun 30, 2025   
    Conversely, while newly approved HS medications such as secukinumab and bimekizumab show promise for the general population, further research is necessary to evaluate their safety profiles in pregnant and breastfeeding individuals. The scant research available on HS in pregnant and lactating women, also shown by our systematic literature review, highlights the need for a comprehensive investigation into the safety, efficacy, and suitability of management strategies.
  • ||||||||||  Goofice (elobixibat) / Ipsen
    Journal:  Efficacy of elobixibat for elderly patients with chronic constipation in a clinic. (Pubmed Central) -  Jun 27, 2025   
    No significant differences were found in the improvement of bowel movement status or the incidence of adverse events between patients with chronic constipation aged < 65 years and ? 65 years, suggesting that the drug may be safely used in elderly patients.
  • ||||||||||  Cervidil (dinoprostone) / Ferring
    Trial completion, Trial completion date, Trial primary completion date:  IV PAPAVERINE Prior to Propess for Labor Induction (clinicaltrials.gov) -  Jun 27, 2025   
    P4,  N=110, Completed, 
    65 years, suggesting that the drug may be safely used in elderly patients. Not yet recruiting --> Completed | Trial completion date: Aug 2026 --> Mar 2025 | Trial primary completion date: Aug 2026 --> Mar 2025
  • ||||||||||  Cervidil (dinoprostone) / Ferring
    Retrospective data, Journal:  Machine learning algorithms to predict epidural-related maternal fever: a retrospective study. (Pubmed Central) -  Jun 26, 2025   
    Furthermore, the LR-based nomogram identified eight significant predictors of ERMF, including neutrophil percentage, first stage of labor, amniotic fluid contamination during membrane rupture, artificial rupture of membranes, chorioamnionitis, post-analgesic antimicrobials, pre-analgesic oxytocin, post-analgesic oxytocin, and dinoprostone suppositories. Optimally applying logistic regression models can enable rapid and straightforward identification of ERMF risk and the implementation of rational therapeutic measures, in contrast to machine learning models.
  • ||||||||||  Cervidil (dinoprostone) / Ferring
    Trial completion, Trial completion date:  COLIGROW: Cook (clinicaltrials.gov) -  Jun 11, 2025   
    P3,  N=172, Completed, 
    Overall effectiveness, perinatal and maternal safety are comparable between outpatient setting cervical ripening with a mechanical method and inpatient with any method. Recruiting --> Completed | Trial completion date: Sep 2025 --> May 2025
  • ||||||||||  Vowst (fecal microbiota spores, live-brpk) / Seres Therap, Nestle, Rebyota (fecal microbiota, live-jslm) / Ferring
    Review, Journal:  Fecal microbiota transplantation: present and future. (Pubmed Central) -  Jun 5, 2025   
    Emerging therapies such as VE303 (Vedanta) are being studied to refine treatment approaches and expand the use of microbiota-based therapies. Further studies are needed to standardize guidelines, improve patient outcomes, and better define the role of FMT in the treatment of diseases beyond recurrent CDI.
  • ||||||||||  methotrexate / Generic mfg., cyclosporine / Generic mfg., Cimzia (certolizumab pegol) / Astellas, UCB
    Journal:  Gender perspective in the management of psoriasis. (Pubmed Central) -  Jun 5, 2025   
    Therefore, it is important to consider a gender perspective in the treatment of psoriasis, including her willingness to procreate. This is a narrative review highlighting the challenges that the healthcare dermatologists may face regarding management of psoriasis in female patients.
  • ||||||||||  Biomarker, Review, Journal:  Pharmacogenomics of TNF inhibitors. (Pubmed Central) -  Jun 5, 2025   
    HLA variants have been linked to heterogeneity in the efficacy and safety of TNFi among patients. Building on the summarized evidence, the last part of the review discusses the potential clinical utility of testing for pharmacogenetic variants that are linked to the response to TNFi prior to the drug prescription, and it also addresses the future directions to achieve personalized treatment for TNFi users.
  • ||||||||||  Journal:  Characterization of intestinal transporters in human ileal spheroid-derived differentiated cells for the prediction of intestinal drug absorption. (Pubmed Central) -  May 29, 2025   
    The functional expression of CYP3A, CYP2C9, UGT1A, P-glycoprotein, and breast cancer resistance protein (BCRP) was confirmed based on the formation of metabolites (1'-hydroxy midazolam, 4'-hydroxy diclofenac, raloxifene-4'-glucuronide, and raloxifene-6-glucuronide) and the efflux ratio of typical substrates (digoxin, sulfasalazine, rosuvastatin, dantrolene, and furosemide). Terminal ileum-derived differentiated cell monolayers showed extensive taurocholic acid-d5 transport in the apical-to-basal direction, which was markedly inhibited by the ASBT inhibitor elobixibat...To date, there is no in
  • ||||||||||  EXPLORING THE IMPACT OF BIOLOGIC THERAPIES ON SARCOPENIA IN RHEUMATOID ARTHRITIS () -  May 28, 2025 - Abstract #EULAR2025EULAR_4059;    
    Terminal ileum-derived differentiated cell monolayers showed extensive taurocholic acid-d5 transport in the apical-to-basal direction, which was markedly inhibited by the ASBT inhibitor elobixibat...To date, there is no in Corticosteroid treatment was received by 98% (n=51) of the patients, with an average dose of 6
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, Rituxan (rituximab) / Roche, Cimzia (certolizumab pegol) / Astellas, UCB
    UNRAVELING THE INFLUENCE OF RHEUMATOID FACTOR ON RA TREATMENT SUCCESS () -  May 28, 2025 - Abstract #EULAR2025EULAR_4028;    
    This effect was not observed with CZP, RTX, or JAKi, suggesting that the influence of RF on therapeutic response may vary depending on the structural properties of the drug. These findings highlight the need to consider RF levels when tailoring treatment strategies for RA patients.
  • ||||||||||  Olumiant (baricitinib) / Eli Lilly, Cimzia (certolizumab pegol) / Astellas, UCB
    GENDER'S INFLUENCE OF INFLAMMATION AND REMISSION IN RHEUMATOID ARTHRITIS  () -  May 28, 2025 - Abstract #EULAR2025EULAR_3952;    
    As a consequence, according to our findings, DAS28CRP might be more appropriate for monitoring treatment response in women and DAS28ESR in men, which should be confirmed in larger/different RA cohorts. There is no strong evidence of a direct association between sex and CDAI-defined remission.
  • ||||||||||  methotrexate / Generic mfg.
    IMPORTANCE OF FC REGION ON THERAPEUTIC SURVIVAL IN RHEUMATOID ARTHRITIS PATIENTES WITH ANTI-TNF THERAPY () -  May 28, 2025 - Abstract #EULAR2025EULAR_3847;    
    We report on a higher percentage of drug withdrawal in patients with RA and anti-TNF treatment with Fc region in their structure, as well as in those cases with higher titers of RF. In addition, we observed a greater therapeutic survival in treatments with low titers of RF and anti-TNF drug without Fc region than in other groups.
  • ||||||||||  Tremfya (guselkumab) / J&J
    SPANISH COHORT OF PSORIATIC ARTHRTIS PATIENTS TREATED WITH GUSELKUMAB () -  May 28, 2025 - Abstract #EULAR2025EULAR_3761;    
    The drug showed high persistence (84.31% in the first year) in a more complex patient profile than those examined in clinical trials. There were no notable adverse events that compromised patient safety or justified drug withdrawal.